Valo Health

Today,?Charles River Laboratories?announced that Logica? identified an advanceable product candidate for the treatment of different forms of lupus and other autoimmune conditions.?? ? Our collaboration with?Charles River Laboratories?leverages the power of the Opal Computational Platform?, an AI-powered platform built to accelerate drug development, and Charles River Laboratories’ leading expertise in drug discovery and preclinical development.? ? The early success of Logica??in identifying this potential therapy builds confidence in our shared goal, and we are excited for our continued work with Charles River Laboratories.? ? Learn more about this discovery: https://lnkd.in/ezfgB2nM ? #DrugDiscovery #DrugDevelopment #AIinMedicine

We are pleased to introduce Peggy Dalicandro as our Vice President, Head of Human Resources. Peggy has already added so much value to our growing team, and we are excited to have her experience and enthusiasm to help us serve populations with AI-enabled drug discovery and development.? ?? Learn more about Peggy’s role at Valo and her prior experience: https://lnkd.in/eMfHNVei ?? #HumanResources #TalentAcquisition??

We're partnering with nference to accelerate innovation by combining the Opal Computational Platform? with neference's Agentic AI. The collaboration gives us access to nference's extensive biomedical knowledge base which includes de-identified insights from leading medical centers. ? ? With these rich, real-world data and advanced analytics, we can improve our research, refine experiments, and drive the discovery of new drug targets and precision medicines. Read more: https://lnkd.in/eMbzi2Jy ? #DrugDiscovery #DrugDevelopment #PrecisionMedicine ??

We rely on robust, high-quality human data to generate new insights into human disease. Through our partnership with?KSM Research & Innovation, we leverage one of the world’s largest biobanks to drive drug discovery and development. Thank you to the KSM team and our collaborators at?Novo Nordisk??– we are just getting started!

We’re at #JPM25, and our CEO Brian Alexander shared insights about AI’s role in drug development. We see AI as a tool to unlock human ingenuity, not replace it. We combine technology, human ingenuity, and real-world data to learn from human models at every stage of drug development.

In Flagship's annual letter, Founder & CEO,?Noubar Afeyan, reflects on polyintelligence – the?synthesis of human, machine, and nature's intelligence. At Valo, we are using our AI-driven Opal platform and skilled team of medical, data science, and machine learning experts to gain new insights from vast amounts of human data. With our unique approach to human-centric AI, we are accelerating drug discovery and development. #FlagshipFounded

We are excited to share that we have entered into an expanded agreement with Novo Nordisk to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on our extensive human real world data (RWD) and computation powered by artificial intelligence. The agreement significantly expands the scope of the collaboration originally signed in 2023 to now enable the discovery and development of up to 20 novel drug programs across an expanded therapeutic landscape. Learn more: https://lnkd.in/eQYgQ38E

?? It's with great pleasure that we announce the elevation of our very own Brett Blackman to his new role as Valo's COO! ?? As a co-founder of Valo, Brett has been an integral leader of our team from its inception.?His contributions have been key to strategically shape the way Valo reimagines the use of human data throughout the entire drug discovery cycle.?Brett's appointment as Chief Operating Officer solidifies Valo's mission, strategic vision and the direction of our growth as we scale our operations into 2025. Join us in celebrating another win for Valo and Valo's leadership team!

?? We’re thrilled to announce the appointment of Brian Alexander as Valo's new CEO! ?? With a people-centric approach, Brian brings two decades of biotechnology, biopharma, and medical expertise and has a stellar record of successful leadership in healthcare innovation across a wide range of different companies and organizations. His appointment as CEO builds on his expertise leveraging cutting-edge technologies to accelerate drug discovery and deliver transformative medicines to patients worldwide. Brian's appointment signals a new era for Valo, building on our strong?foundation to advance our Opal Platform and accelerate our human-centric approach to drug discovery and development. Join us in welcoming Brian to lead the Valo team!

We're thrilled to announce another collaborative Valo manuscript has been published ?? highlighting the power of our translational 3D engineered tissue models to recapitulate human biological mechanisms. This marks another positive stride toward improving drug discovery and development. Valo's proprietary capability to perform human cardiac functional tissue experiments in vitro ?? has now demonstrably been extended to skeletal muscle ?? adding enormous insights beyond standard 2D models and animal models. Special thanks to co-lead authors Isabella Pallotta, Ph.D. (Valo Health) and Michael Stec (Regeneron) for their partnership ?? on this outstanding work.? Check out the paper today in the Journal: Physiological Reports ??. ? ?? Valo is committed to discovering and developing novel medicines for a variety of therapeutic areas including cardiometabolic diseases, spanning a range of conditions including Type 2 Diabetes, obesity, hypertension, chronic kidney disease and dyslipidemia. Many skeletal muscle disorders remain untreated, in part due to a lack of predictive human models for use in therapeutic development. In this manuscript, we engineered human skeletal muscle tissues for the first time on Valo’s Biowire platform, demonstrating structural and physiological features similar to human skeletal muscle. The Biowire skeletal tissues respond to both exercise (electrical stimulation) and drug treatment with expected adaptations including changes in the force of tissue contraction and fatigue resistance. We believe our 3D human skeletal model will shed light on mechanisms underlying a variety of diseases including pathological fatigability and metabolism that today are still poorly understood and untreated ??.